Lung cancer remains the leading cause of cancer death worldwide and non-small-cell lung cancer (NSCLC) accounts for 80% of lung cancer. During the last several decades, tremendous progress in understanding lung cancer biology and development of technology has been achieved, leading to improvement in screening, diagnosis, molecular biology, and management including chemotherapy, targeted therapy and radiotherapy. In this issue, each part of NSCLC field will be discussed by several experts. During 1980's, only K-ras mutation has been known to be involved in the development of NSCLC. Since EGFR mutation, the landmark biomarker was found in 2004, substantial development in understanding of molecular biology of lung cancer has been achieved especially in adenocarcinoma of lung and even in squamous cell carcinoma recently. Identification of EGFR mutation and development of its targeted agent, EGFR tyrosine kinase inhibitor has shed light on personalized therapy in NSCLC, in which oncogenic addiction has been proved to exist even in solid tumors.
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Choi will extensively review the molecular biology of NSCLC including several oncogenes (EGFR, K-ras, ALK, RET, ROS1, and FGFR1), tumor suppressor genes (p53, CDK/p16/RB, and LKB1), angiogenesis, epigenetics, microRNA, telomere/telomerase, and cancer stem cells [1] . Accordingly, the importance of detection of these genotypes for personalized therapy and also many unresolved issues regarding new technologies, including next generation sequen cing will be discussed.
NSCLC has been considered one disease along with small cell lung cancer, because several histologically defined subtypes, adenocarcinoma, squamous cell, and large cell carcinoma did not affect the prognosis or management of NSCLC long time before. However, cumulative studies demonstrating the different outcomes for specific chemotherapy or targeted agents according to the underlying histology subtype emphasized the importance of pathology.
Moreover, the growing evidences that lung cancer is heterogeneous and composed of many small molecular subsets according to molecular genotyping, followed by significant improvement of clinical outcomes to specific targeted agents demonstrate the importance of biomarkers along with accurate histological diagnosis of NSCLC. Therefore, aspiration cytology for diagnosis of lung cancer is not acceptable anymore, and large amount of tissue acquisition as much as possible became the critical issue for accurate diagnosis along with molecular genotyping. Jung will discuss in detail the importance of histology in NSCLC and how several molecular tests should be performed efficiently with small biopsy specimen for making treatment decision [2] . Most of NSCLC patients are diagnosed at an advanced stage due to no adequate tool for early detection available despite extensively performed screening programs, leading to high mortality. Recently, low-dose computed tomography (LDCT) has emerged as a promising method for early detection from well-designed randomized trial. Won will review many trials which were conducted for lung cancer screening and also the limitations and possible application of LDCT as screening method for NSCLC [3] .
Staging is critical for making treatment decision especially in NSCLC. Mediastinoscopy has been considered gold standard for staging of mediastinum, but it is invasive and requires general anesthesia. As a non-invasive technique, endobronchial ultrasoundguided transbronchial needle aspiration (EBUS-TBNA) or endoscopic ultrasound-guided fine nee dle aspiration (EUS-FNA) has emerged as a new diagnostic modality which allows not only high sensitivity and specificity for mediastinal staging but obtaining adequate biopsy for molecular genotyping. The advantages and limitations of EBUS will be discussed by Um [4] . Although advances in one specialty area of lung cancer research informed advances in other areas as well and lots of progress has been achieved in NSCLC, we still have a long way to go. Given the complexity of NSCLC, multidisciplinary team approach including biology, molecular biology, epidemiology, pathology, pulmonology, medical oncology, thoracic surgery, radiation oncology, public health and supportive care should be needed to combat this dreaded disease.
